Novel Peripherally Derived Neural-Like Stem Cells as Therapeutic Carriers for Treating Glioblastomas. (14th September 2016)

• Record Type: Journal Article
• Authors: Birbrair, Alexander; Sattiraju, Anirudh; Zhu, Dongqin; Zulato, Gilberto; Batista, Izadora; Nguyen, Van T.; Messi, Maria Laura; Solingapuram Sai, Kiran Kumar; Marini, Frank C.; Delbono, Osvaldo; Mintz, Akiva
• Is Part Of: Stem cells translational medicine. Volume 6:Number 2(2017)
• Page Start: 471
• Page End: 481
• Publication Date: 2016-09-14
• Subjects: Glioblastoma -- Cellular therapy -- Muscle stem cells -- Neural differentiation -- Neural-like stem cells; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.5966/sctm.2016-0007
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract: Glioblastoma (GBM), an aggressive grade IV astrocytoma, is the most common primary malignant adult brain tumor characterized by extensive invasiveness, heterogeneity, and angiogenesis. Standard treatment options such as radiation and chemotherapy have proven to be only marginally effective in treating GBM because of its invasive nature. Therefore, extensive efforts have been put forth to develop tumor-tropic stem cells as viable therapeutic vehicles with potential to treat even the most invasive tumor cells that are harbored within areas of normal brain. To this end, we discovered a newly described NG2-expressing cell that we isolated from a distinct pericyte subtype found abundantly in cultures derived from peripheral muscle. In this work, we show the translational significance of these peripherally derived neural-like stem cells (NLSC) and their potential to migrate toward tumors and act as therapeutic carriers. We demonstrate that these NLSCs exhibit in vitro and in vivo GBM tropism. Furthermore, NLSCs did not promote angiogenesis or transform into tumor-associated stromal cells, which are concerns raised when using other common stem cells, such as mesenchymal stem cells and induced neural stem cells, as therapeutic carriers. We also demonstrate the potential of NLSCs to express a prototype therapeutic, tumor necrosis factor α-related apoptosis-inducing ligand and kill GBM cells in vitro. These data demonstrate the therapeutic potential of our newly characterized NLSC against GBM.